Townsend v. Brooks Sports, Inc.

CourtDistrict Court, W.D. Washington
DecidedMarch 31, 2024
Docket2:17-cv-01322
StatusUnknown

This text of Townsend v. Brooks Sports, Inc. (Townsend v. Brooks Sports, Inc.) is published on Counsel Stack Legal Research, covering District Court, W.D. Washington primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Townsend v. Brooks Sports, Inc., (W.D. Wash. 2024).

Opinion

1 2 3 4 5

6 7 UNITED STATES DISTRICT COURT 8 WESTERN DISTRICT OF WASHINGTON AT SEATTLE 9 10 HERBERT E. TOWNSEND, CASE NO. 2:17-cv-01322-LK 11 Plaintiff, ORDER DENYING MOTION FOR 12 v. ATTORNEY FEES 13 BROOKS SPORTS, INC., 14 Defendant. 15

16 Plaintiff Herbert Townsend sued Brooks Sports, Inc. in the Middle District of Florida for 17 infringement of claim 1 of U.S. Patent No. 7,490,416 (the “’416 Patent”). Brooks Sports 18 countersued for a declaratory judgment of non-infringement and invalidity. After the case was 19 transferred to this district, Brooks Sports successfully petitioned the Patent Trial and Appeal Board 20 (the “PTAB”) for inter partes review of claim 1. The Court accordingly stayed these proceedings 21 pending the PTAB’s decision. The PTAB ultimately found claim 1 unpatentable, and the Federal 22 Circuit summarily affirmed that decision. The parties then returned to this Court, agreed to lift the 23 stay, and stipulated to dismissal of Townsend’s infringement claim with prejudice and Brooks 24 Sports’ counterclaim without prejudice. 1 Brooks Sports now moves for over $1 million in attorney fees under Section 285 of the 2 Patent Act. Dkt. No. 127. It contends that Townsend failed to conduct a reasonable pre-suit 3 investigation and litigated this case in an unreasonable manner. The Court disagrees. Because this 4 case does not as a whole stand out from the mine-run infringement suit, the Court denies Brooks 5 Sports’ motion.1

6 I. BACKGROUND 7 The origins of this lawsuit stretch back roughly seven years. The Court surveys early 8 communications between the parties and summarizes the procedural history of this case to 9 contextualize its discussion of Townsend’s pre-suit investigation and litigation conduct. 10 A. Townsend and the ’416 Patent 11 Townsend owns the ’416 Patent. Dkt. No. 1 at 2. Issued in February 2009 by the United 12 States Patent and Trademark Office, the ’416 Patent is titled “Shoe with Cushioning and Speed 13 Enhancement Midsole Components and Method for Construction Thereof.” Id.; see Dkt. No. 15- 14 1 (the ’416 Patent); U.S. Patent No. 7,490,416 (filed Nov. 23, 2004) (issued Feb. 17, 2009). The

15 patent abstract indicates that the protected invention is a running shoe with “improved cushioning 16 and energy returning properties that vary depending upon the speed of the runner due to 17 incorporation of at least one insert containing dilatant compound encapsulated in a shell and set 18 into the midsole of the running shoe[.]” Dkt. No. 15-1 at 1; see also id. at 8, col. 3 l. 10–12 (“[T]he 19 present invention describes an improved running shoe having a midsole with a modulus of 20 elasticity and yield point that increase at higher running speeds.”). Although the ’416 Patent 21 consists of eleven claims, only claim 1 is relevant here. Claim 1 is as follows: 22 1. A shoe to be worn on a foot, said shoe comprising a midsole having a top surface, said shoe midsole fabricated from material having a fixed elastic modulus and 23 1 Because the Court can decide the matter based on the parties’ filings, it denies Brooks Sports’ request for oral 24 argument. 1 having at least one cavity formed in said top surface below the bottom of the foot, said at least one cavity filled with material consisting essentially of a dilatant 2 compound, all of which material consisting essentially of a dilatant compound is retained below the bottom of the foot. 3 Id. at 10, col. 8 l. 27–35. The ’416 Patent further specifies that, “[f]or purposes of this invention, a 4 dilatant compound is a polymeric material that changes from soft and pliable under slow 5 application of a load to elastic and bouncy under rapid application of a load.” Id. at 7, col. 2 l. 39– 6 42. Put differently, a dilatant compound is “a liquid with inverse thixotropy, that is, a viscous liquid 7 suspension that temporarily solidifies under applied pressure.” Id. at 7, col. 2 l. 45–47. It is “derived 8 from a mixture of dimethyl siloxane, hydroxy-terminated polymers with boric acid, Thixotrol ST® 9 brand organic rheological additive manufactured by Elementis Specialties, Inc., 10 polydimethy[l]siloxane, decamethyl cyclopentasiloxane, glycerin, and titanium dioxide.” Id. at 8, 11 col. 4 l. 16–21. 12 B. Brooks Sports and the ’885 Patent 13 Brooks Sports is a Washington corporation that “makes, imports, sells and/or offers for 14 sale running shoes that include a material in the midsole to provide cushioning.” Dkt. No. 1 at 3. 15 It is the owner by assignment of U.S. Patent No. 8,209,885 (the “’885 Patent”). Id. Issued in July 16 2012 by the United States Patent and Trademark Office, the ’885 Patent is titled “Shoe Assembly 17 with Non-Linear Viscous Liquid.” Id.; see Dkt. No. 15-2 (the ’885 Patent); U.S. Patent No. 18 8,209,885 (filed May 11, 2009) (issued Jul. 3, 2012). The abstract states that the protected 19 invention consists of “a shoe and shoe sole assembly made of a non-linearly viscous, SEBS block 20 copolymer-based material that becomes more resilient as more energy is applied.” Dkt. No. 15-2 21 at 1. Other embodiments entail “non-linearly viscous, SEBS block copolymer-based 22 material . . . mixed with at least one other polymer in a foam,” where “[t]he midsole is formed with 23 a heel impact region and a forefoot region made of the foam.” Id. The ’885 Patent recognizes 24 1 “previous attempts [to] place a bladder or insert in the sole containing air, gel, plastic, or other 2 material to absorb impact,” but dismisses those materials as inadequate because they fail to provide 3 the necessary “range of response characteristics to different levels of pressure and impact.” Id. at 4 6, col. 1 l. 32–36. Indeed, the ’885 Patent expressly refers to the shortcomings of dilatants: 5 Some attempts have been made to provide a shoe with dilatant (i.e., shear- thickening) materials in the sole. These materials increase in viscosity as a function 6 of the rate of shear (e.g., silly putty). Dilatant materials, however, are generally not accurately calibrated to the responsiveness required for multiple levels of activity 7 to provide optimal responsiveness and comfort. Also, dilatant materials cannot be readily injection molded or compression molded, increasing the complexity and 8 cost of manufacture. 9 Id. at 6, col. 1 l. 43–51. 10 Brooks Sports refers to the “adaptive cushioning” material protected under the ’885 Patent 11 as “Brooks DNA”—a product it describes in advertisements as “a highly viscous non-Newtonian 12 material” that “adapts to the specific force you apply to it.” Dkt. No. 1 at 3. Brooks Sports has 13 made, imported, and sold running shoes with midsoles made of Brooks DNA or “made of material 14 in which Brooks DNA is blended with another material to provide Brooks DNA cushioning 15 throughout the midsole.” Id. 16 C. Townsend Accuses Brooks Sports of Infringing the ’416 Patent: Early Communications 17 In February 2016, Townsend’s counsel authored a letter to Brooks Sports’ Chief Executive 18 Officer and Director claiming that Brooks DNA “embodies technology that is disclosed and 19 claimed by Mr. Townsend’s 416 Patent.” Dkt. No. 130-1 at 2. Counsel indicated that Townsend 20 was “willing to consider granting Brooks rights under his 416 Patent,” and requested a response 21 setting forth Brooks Sports’ “position on this patent and the relevance of this patent to Brooks 22 shoes that include Brooks ‘DNA’ ‘adaptive cushioning.’” Id. Brooks Sports’ corporate counsel 23 responded by email in April 2016. Dkt. No. 130-2 at 2. Corporate counsel indicated that Brooks 24 1 Sports had “confirmed that the Brooks DNA technology falls outside the claims of the ’416 2 Townsend patent . . . because Brooks’ DNA material is not a dilatant compound (a requirement of 3 every claim of the Townsend patent).” Id. (asserting that Brooks DNA “is specifically a non- 4 dilatant material that provides superior performance results”).

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Eon-Net LP v. Flagstar Bancorp
653 F.3d 1314 (Federal Circuit, 2011)
In Re Cordis Corporation
769 F.2d 733 (Federal Circuit, 1985)
United States v. Ramos-Gonzalez
664 F.3d 1 (First Circuit, 2011)
Richard L. Conkling v. Bert S. Turner
18 F.3d 1285 (Fifth Circuit, 1994)
Lozano v. Montoya Alvarez
134 S. Ct. 1224 (Supreme Court, 2014)
Sfa Systems, LLC v. Newegg Inc.
793 F.3d 1344 (Federal Circuit, 2015)
Bayer Cropscience Ag v. Dow Agrosciences LLC
851 F.3d 1302 (Federal Circuit, 2017)
TC Heartland LLC v. Kraft Foods Group Brands LLC
581 U.S. 258 (Supreme Court, 2017)
Adjustacam, LLC v. Newegg, Inc.
861 F.3d 1353 (Federal Circuit, 2017)
In Re: Cray Inc.
871 F.3d 1355 (Federal Circuit, 2017)
Raniere v. Microsoft Corporation
887 F.3d 1298 (Federal Circuit, 2018)
Stone Basket Innovations, LLC v. Cook Medical LLC
892 F.3d 1175 (Federal Circuit, 2018)
Spineology, Inc. v. Wright Medical Technology Inc.
910 F.3d 1227 (Federal Circuit, 2018)
Thermolife International LLC v. Gnc Corporation
922 F.3d 1347 (Federal Circuit, 2019)
Arthrex, Inc. v. Smith & Nephew, Inc.
941 F.3d 1320 (Federal Circuit, 2019)

Cite This Page — Counsel Stack

Bluebook (online)
Townsend v. Brooks Sports, Inc., Counsel Stack Legal Research, https://law.counselstack.com/opinion/townsend-v-brooks-sports-inc-wawd-2024.